2nd Quarter - Report

HOSPIRA, INC. for HOSPIRA INC

Firm
Client
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming. Issues relating to opiate overdosing. Issues related to drug approvals at the FDA including biosimilars.

LobbyistCovered position, as disclosed
JULIANA REED —
WENDY SUSSMAN —

Contacted: White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Issues relating to drug shortages, patent use codes and drug labeling (RIN:0910-AG94: FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products).

LobbyistCovered position, as disclosed
JULIANA REED —
WENDY SUSSMAN —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.